ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages CareDx, Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation CDNA

WHY: New York, NY – (NewMediaWire) – January 25, 2022 – Rosen Law Firm, a global investor
rights law firm, continues to investigate potential securities claims on behalf
of shareholders of CareDx, Inc. (NASDAQ: CDNA) resulting from allegations that CareDx may have issued materially misleading
business information to the investing public.

SO WHAT: If you purchased CareDx securities you may be entitled to
compensation without payment of any out of pocket fees or costs through a
contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking
recovery of investor losses.

WHAT TO DO
NEXT: To join the
prospective class action, go to http://www.rosenlegal.com/cases-register-2197.html or call Phillip Kim, Esq.
toll-free at 866-767-3653 or email pkim@rosenlegal.com
or cases@rosenlegal.com for
information on the class action.

WHAT IS THIS
ABOUT: On January 25, 2021, CareDx sold 1,923,077 shares of its common stock through
an underwritten public offering at a public offering price of $91.00 per share.

Then October 28,
2021, after the market closed, CareDx released third quarter 2021 financial
results in which the Company disclosed that the U.S. Department of Justice
(“DOJ”) served a civil investigatory demand requesting documents in connection
with a False Claims Act investigation. The DOJ is investigating business
practices related to CareDx’s kidney testing and phlebotomy services. The
Company also disclosed that it received a subpoena from the U.S. Securities and
Exchange Commission (“SEC”) for similar issues, as well as certain accounting
and public reporting practices, and the Company received an information request
from an unnamed state agency.

On this news, the
Company’s share price declined by $19.34 per share, or 27%, to close at $51.00
per share on October 29, 2021.